StockNews.com started coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a research note issued to investors on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock.
Several other equities analysts have also issued reports on ALIM. Zacks Investment Research upgraded Alimera Sciences from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 27th. HC Wainwright decreased their price objective on Alimera Sciences from $10.00 to $8.00 in a research report on Tuesday. Finally, Alliance Global Partners reduced their price target on Alimera Sciences from $14.50 to $11.00 in a research report on Friday, February 25th.
Shares of ALIM opened at $4.00 on Friday. The stock has a 50 day simple moving average of $5.53 and a 200 day simple moving average of $5.10. Alimera Sciences has a 52-week low of $3.94 and a 52-week high of $10.50. The firm has a market capitalization of $27.97 million, a PE ratio of -5.06 and a beta of 1.48.
A number of large investors have recently added to or reduced their stakes in ALIM. Millennium Management LLC acquired a new position in Alimera Sciences during the 4th quarter worth approximately $65,000. Ensign Peak Advisors Inc acquired a new position in Alimera Sciences during the 3rd quarter worth approximately $81,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Alimera Sciences during the 1st quarter worth approximately $1,400,000. Finally, Morgan Stanley raised its stake in shares of Alimera Sciences by 0.7% during the 2nd quarter. Morgan Stanley now owns 428,109 shares of the biopharmaceutical company’s stock worth $3,896,000 after purchasing an additional 2,797 shares in the last quarter. 40.97% of the stock is owned by hedge funds and other institutional investors.
Alimera Sciences Company Profile (Get Rating)
Alimera Sciences, Inc, a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
- Get a free copy of the StockNews.com research report on Alimera Sciences (ALIM)
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.